PMID- 38261515
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 2211-1247 (Electronic)
VI  - 43
IP  - 2
DP  - 2024 Feb 27
TI  - Circulating tumor cells reveal early predictors of disease progression in 
      patients with stage III NSCLC undergoing chemoradiation and immunotherapy.
PG  - 113687
LID - S2211-1247(24)00015-9 [pii]
LID - 10.1016/j.celrep.2024.113687 [doi]
AB  - Circulating tumor cells (CTCs) are early signs of metastasis and can be used to 
      monitor disease progression well before radiological detection by imaging. Using 
      an ultrasensitive graphene oxide microfluidic chip nanotechnology built with 
      graphene oxide sheets, we were able to demonstrate that CTCs can be specifically 
      isolated and molecularly characterized to predict future progression in patients 
      with stage III non-small cell lung cancer (NSCLC). We analyzed CTCs from 26 
      patients at six time points throughout the treatment course of chemoradiation 
      followed by immune checkpoint inhibitor immunotherapy. We observed that CTCs 
      decreased significantly during treatment, where a larger decrease in CTCs 
      predicted a significantly longer progression-free survival time. 
      Durvalumab-treated patients who have future progression were observed to have 
      sustained higher programmed death ligand 1+ CTCs compared to stable patients. 
      Gene expression profiling revealed phenotypically aggressive CTCs during 
      chemoradiation. By using emerging innovative bioengineering approaches, we 
      successfully show that CTCs are potential biomarkers to monitor and predict 
      patient outcomes in patients with stage III NSCLC.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Purcell, Emma
AU  - Purcell E
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Niu, Zeqi
AU  - Niu Z
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Owen, Sarah
AU  - Owen S
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Grzesik, Madeline
AU  - Grzesik M
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Radomski, Abigail
AU  - Radomski A
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Kaehr, Anna
AU  - Kaehr A
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Onukwugha, Nna-Emeka
AU  - Onukwugha NE
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Winkler, Heather Fairbairn
AU  - Winkler HF
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA.
FAU - Ramnath, Nithya
AU  - Ramnath N
AD  - Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA.
FAU - Lawrence, Theodore
AU  - Lawrence T
AD  - Michigan Medicine, Department of Radiation Oncology, Ann Arbor, MI 48105, USA; 
      Rogel Cancer Center, Ann Arbor, MI 48105, USA.
FAU - Jolly, Shruti
AU  - Jolly S
AD  - Michigan Medicine, Department of Radiation Oncology, Ann Arbor, MI 48105, USA; 
      Rogel Cancer Center, Ann Arbor, MI 48105, USA. Electronic address: 
      shrutij@med.umich.edu.
FAU - Nagrath, Sunitha
AU  - Nagrath S
AD  - Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, 
      USA; Rogel Cancer Center, Ann Arbor, MI 48105, USA. Electronic address: 
      snagrath@umich.edu.
LA  - eng
PT  - Journal Article
DEP - 20240122
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
RN  - 0 (graphene oxide)
RN  - 7782-42-5 (Graphite)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Neoplastic Cells, Circulating/metabolism
MH  - *Lung Neoplasms
MH  - Immunotherapy
MH  - Disease Progression
MH  - *Graphite
OTO - NOTNLM
OT  - CP: Cancer
OT  - CTCs
OT  - NSCLC
OT  - cancer biomarkers
OT  - chemoradiation
OT  - circulating tumor cells
OT  - durvalumab
OT  - immunotherapy
OT  - liquid biopsy
OT  - lung cancer
OT  - microarray
COIS- Declaration of interests The authors declare no competing interests.
EDAT- 2024/01/23 18:42
MHDA- 2024/03/04 06:50
CRDT- 2024/01/23 12:36
PHST- 2023/03/10 00:00 [received]
PHST- 2023/11/02 00:00 [revised]
PHST- 2024/01/02 00:00 [accepted]
PHST- 2024/03/04 06:50 [medline]
PHST- 2024/01/23 18:42 [pubmed]
PHST- 2024/01/23 12:36 [entrez]
AID - S2211-1247(24)00015-9 [pii]
AID - 10.1016/j.celrep.2024.113687 [doi]
PST - ppublish
SO  - Cell Rep. 2024 Feb 27;43(2):113687. doi: 10.1016/j.celrep.2024.113687. Epub 2024 
      Jan 22.